Shots:
- GSK has entered an agreement to acquire Nuvalent, accelerating its entry into lung cancer
- As per the deal, GSK will acquire Nuvalent through a tender offer of $124 per share in cash, valuing the company at ~$10.6B (£8.0B); net of acquired cash, GSK’s total investment is estimated at $9.4B (£7.1B). Closing is expected in Q3’26
- Nuvalent’s portfolio incl. zidesamtinib (ROS1 inhibitor) & neladalkib (ALK inhibitor), two late-stage NSCLC assets under FDA review with target decision dates of Sep 18, 2026 & Nov 27, 2026, respectively, & launch expected by 2026, plus P-I HER2 inhibitor NVL-330 for HER2-altered NSCLC & a preclinical pipeline
Ref: GSK | Image: Nuvalent | Press Release
Related News: Engitix and GSK Partner on Human ECM Platform to Identify Liver Fibrosis Regression Targets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
